Pharvaris N.V.
PHVS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PHVS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PHVS
Pharvaris N.V. is a clinical-stage biopharmaceutical company developing deucrictibant, an oral bradykinin B2 receptor antagonist, for the treatment of hereditary angioedema (HAE) and other bradykinin-mediated conditions.
Key risk: No approved products
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2025.
Tracking 8 clinical trials · 3 catalysts for Pharvaris N.V..
Pharvaris N.V. is a clinical-stage biopharmaceutical company developing deucrictibant, an oral bradykinin B2 receptor antagonist, for the treatment of hereditary angioedema (HAE) and other bradykinin-mediated conditions.
- Pharvaris has no approved drugs and has not recorded any revenues as of its latest annual report [sec · filed 2026-04-02].
- The company reported shareholders' equity of $384.0M as of 2025-12-31 [sec].
- Pharvaris is focused on the clinical development of deucrictibant immediate-release (IR) and extended-release (XR) formulations for HAE [sec · filed 2026-04-02].
- The company expects to file a New Drug Application (NDA) for deucrictibant IR with the U.S. FDA in 2026 [sec · filed 2026-04-02].
- Pharvaris has completed Phase 1 and Phase 2 studies in HAE and is conducting a Phase 3 program for deucrictibant [sec · filed 2026-04-02].
What works
- Pharvaris has a strong cash position with shareholders' equity of $384.0M as of 2025-12-31, providing a multi-year runway to advance its pipeline [sec].
- The company is approaching a key regulatory milestone with an NDA submission for deucrictibant IR planned in 2026, which could lead to first commercial product [sec · filed 2026-04-02].
- Deucrictibant is an oral therapy that could offer a convenient alternative to injectable treatments for HAE, potentially addressing a large unmet need [sec · filed 2026-04-02].
What to weigh
- Pharvaris has no approved products and has never generated revenue, making it entirely dependent on the success of deucrictibant [sec · filed 2026-04-02].
- Clinical development is inherently uncertain; the company may face delays, negative trial results, or failure to obtain regulatory approval, which could materially harm its prospects [sec · filed 2026-04-02].
- The company expects research and development expenses to increase in 2026, and it may need to raise additional capital if its cash runway is insufficient to complete development [sec · filed 2026-04-02].
- Pharvaris operates in a competitive landscape with existing approved therapies for HAE, and deucrictibant may not achieve commercial adoption even if approved [sec · filed 2026-04-02].
From the filings
Quoted directly from source documents.
Pharvaris has no approved drugs and no revenue.
“We do not have any drugs that have received regulatory approval and may never be able to develop marketable products.”
SEC filings · April 2, 2026
Pharvaris plans to file an NDA for deucrictibant IR in 2026.
“filing the NDA application in the U.S. in 2026 and development of our XR product candidate”
SEC filings · April 2, 2026
Pharvaris has completed Phase 2 studies in HAE.
“Phase 2 studies in people living with HAE of deucrictibant for both treatment and prophylaxis of HAE attacks”
SEC filings · April 2, 2026
Catalyst timeline
- 2027-06-01 · Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, 3-Part Study to Evaluate the Efficacy and Safety of Orally Administered Deucrictibant for the Acute Treatment of Angioedema Attacks in Participants with HAE — This topline data will assess the efficacy and safety of deucrictibant IR in acute HAE attacks, a key milestone for regulatory filing.
- 2027-06-01 · Phase 3 Topline: A Phase II/III, Extension Study of Orally Administered PHA-022121 for Acute Treatment of Angioedema Attacks in Patients with HAE — This extension study topline will provide longer-term safety and efficacy data for deucrictibant IR in acute treatment.
- 2028-12-01 · Phase 3 Topline: A Long-term, Open-label Study to Evaluate the Safety and Efficacy of Orally Administered Deucrictibant Extended-Release (XR) Tablets for the Prophylaxis of Angioedema Attacks in Patients with HAE — This topline data will evaluate the prophylactic potential of deucrictibant XR, supporting a potential label expansion.
Risks & what to watch (4)›
Key risks
- No approved products — Pharvaris has no drugs approved for marketing and may never develop marketable products [sec · filed 2026-04-02].
- Clinical development risk — Clinical trials may fail to show efficacy or safety, leading to delays or inability to obtain regulatory approval [sec · filed 2026-04-02].
- Need for additional capital — The company may need to raise additional funds if expenses exceed current cash, potentially diluting shareholders [sec · filed 2026-04-02].
- Competitive market — Existing approved HAE therapies may limit deucrictibant's commercial potential even if approved [sec · filed 2026-04-02].
What to watch
- NDA submission for deucrictibant IR to the U.S. FDA, expected in 2026 [sec · filed 2026-04-02].
- Phase 3 topline data readouts for deucrictibant IR and XR, expected in 2027 and 2028 [upcoming catalysts].
- Progress of the Phase 2/3 extension study for deucrictibant IR in acute HAE treatment [upcoming catalysts].
- Any updates on cash runway or additional financing needs as R&D expenses increase [sec · filed 2026-04-02].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run Pharvaris N.V. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Pharvaris N.V. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Cash runway data unavailable
D/E 0.11
No tracked pipeline phase
No tracked pipeline candidates
3 upcoming, next in ~275d
0 buys · 53 sells (180d)
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
108
Total value held
$1.32B
| Holder | Shares | Value |
|---|---|---|
| general atlantic, l.p. | 8,031,252 | $226.9M |
| fmr llc | 6,284,472 | $177.5M |
| viking global investors lp | 3,653,310 | $103.2M |
| eqt fund management s.a r.l. | 3,424,609 | $96.7M |
| deerfield management company, l.p. | 3,126,042 | $88.3M |
| wellington management group llp | 2,118,900 | $59.9M |
| commodore capital lp | 1,918,970 | $54.2M |
| novo holdings a/s | 1,750,000 | $49.4M |
| saturn v capital management lp | 1,201,402 | $33.9M |
| point72 asset management, l.p. | 1,007,016 | $28.4M |
Showing top 10 of 108 institutional holders of Pharvaris N.V.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 2.0%
- Days to cover
- 3.8
- Shares short
- 1,051,478
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PHVS short interestFrequently asked questions
What is the AI investment thesis for Pharvaris N.V.?
Pharvaris N.V. is a clinical-stage biopharmaceutical company developing deucrictibant, an oral bradykinin B2 receptor antagonist, for the treatment of hereditary angioedema (HAE) and other bradykinin-mediated conditions.
What is Pharvaris N.V.'s next catalyst?
Pharvaris N.V.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, 3-Part Study to Evaluate the Efficacy and S" — expected June 1, 2027.
Who is the CEO of Pharvaris N.V.?
Mr. Berndt Axel Edvard Modig CPA, M.B.A. is the chief executive officer of Pharvaris N.V. (PHVS).
Where is Pharvaris N.V. headquartered?
Pharvaris N.V. (PHVS) is headquartered in Zug, Switzerland.
What therapeutic areas does Pharvaris N.V. focus on?
Pharvaris N.V. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.